Beyond Anti-VEGF: Next Generation Solutions for Diabetic Retinopathy
Martin A. Due?as
OniX - Connecting Ideas to Opportunities | Biotech Innovation Accelerator | Academic Research to Market | Strategic Partnerships | Funding Strategist
OniX OnPoint Issue 24 delivers a comprehensive overview of diabetic retinopathy (DR) research, highlighting significant developments across sponsored projects, technology transfer, and biotechnology sectors. Leading global institutions are advancing innovative approaches to understanding and treating DR, including novel gut-retina axis modulation, vascular permeability control, and oxidative stress management strategies.
Key highlights include groundbreaking research in ACE2 regulation of gut barrier function at University of Alabama, investigation of CD148's role in vascular permeability at Queen Mary University of London, and innovative studies on ketone body metabolism at Centre hospitalier universitaire Sainte-Justine. The technology transfer landscape showcases promising developments, including enhanced gene transfer technologies from University of Pennsylvania and vascular progenitor developments from Johns Hopkins University.
The biotechnology sector demonstrates strong momentum with companies like Kodiak, Oxurion, and PanOptica developing innovative treatments ranging from anti-VEGF antibodies to novel eye drop solutions. Recent breakthrough studies featured include the discovery of ceramide immunotherapy's potential in reversing DR and the role of transcription factor EB in halting vision loss.
The edition features significant research from institutions across the United States, Japan, Germany, Canada, and United Kingdom, demonstrating a robust international effort to advance diabetic retinopathy treatment options. The integration of novel approaches targeting oxidative stress and vascular regeneration underscores the sophisticated research methods being employed to combat this challenging condition.
Our weekly OniX OnPoint Newsletter and daily LinkedIn Update works in tandem, focusing this week on diabetic retinopathy research and opportunities. Gain insights to identify early-stage assets, connect with key opinion leaders, explore strategic partnerships, and discover licensing opportunities in this rapidly evolving field.
#DiabeticRetinopathy #MedicalResearch #Biotechnology #Innovation #Healthcare #Research #Ophthalmology #GeneTherapy #VascularDiseases #RetinalDiseases